pegilated nanoliposome

aim and background: hepatocellular carcinoma (hcc) -an aggressive malignancy with high rate of mortality- is the third cause of cancer related death, worldwide. cisplatin is a chemotherapy drug used for treatment of hcc. however, serious side effects of drug limit the therapeutic administer dose.  nanotechnology based devices such as liposome nanoparticles are capable to overcome these drawbacks and simultaneously improve the efficacy of drugs. materials and methods: cisplatin encapsulated liposomal nanoparticles were successfully constructed using lecithin, cholesterol, peg3350and cisplatin. after characterization in vitro efficacy of nanodrug was evaluated with ic50 pharm microsoft. results: the size and zeta potential of nanoparticles were determined to be 470 nm and -20 mv. the cytotoxicity of drug loaded nanoparticles was increased by 33% compared to the free drug on the hepatocellular carcinoma cell line hepg2 using mtt assay. conclusion: the results of study suggested evaluating the efficacy of nanodrug on the animal model of hcc and also the cytotoxicity of pegilated nanoliposome drug is more than the free drug.